Page last updated: 2024-11-05

fencamfamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fencamfamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14584
CHEMBL ID7010
CHEBI ID134895
SCHEMBL ID156977
MeSH IDM0075175

Synonyms (36)

Synonym
nme1i5igbk ,
unii-nme1i5igbk
fencamfamina
fencanfamina
2-phenyl-3-ethylaminobicyclo(2.2.1)heptane
fencamfamine [inn-french]
fencamfamin [inn:ban]
euvitol
fenacamfamin
dea no. 1760
fencamfamina [dcit]
bicyclo(2.2.1)heptan-2-amine, n-ethyl-3-phenyl-
reactivan
fencanfamina [inn-spanish]
fencamfaminum [inn-latin]
fencamfamine
fencamfaminum
3-phenyl-n-ethyl-2-norbornanamine
2-ethylamino-3-phenylnorbornane
2-norbornanamine, n-ethyl-3-phenyl-
fencamfamin (inn)
1209-98-9
D07343
DB01463
fencamfamin
phencamphamine
CHEBI:134895
CHEMBL7010
n06ba06
n-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
SCHEMBL156977
n-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine #
IKFBPFGUINLYQI-UHFFFAOYSA-N
Q3742409
DTXSID60862601
femcamfamine

Research Excerpts

Overview

Fencamfamine (FCF) is a psychostimulant drug classified as an indirect dopamine agonist. It is a central stimulant that facilitates central dopaminergic transmission through inhibition of dopamine uptake.

ExcerptReferenceRelevance
"Fencamfamine (FCF) is an indirect dopamine agent with effects similar to amphetamine and cocaine. "( Changes in sodium, potassium-ATPase induced by repeated fencamfamine: the roles of cyclic AMP-dependent protein kinase and the nitric oxide-cyclic GMP pathway.
Araújo, AP; DeLucia, R; Glezer, I; Kawamoto, EM; Lepscha, LB; Munhoz, CD; Planeta, CS; Scavone, C, 2003
)
2.01
"Fencamfamine (FCF) is a psychostimulant classified as an indirect dopamine agonist. "( Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors.
Aizenstein, ML; DeLucia, R; Planeta, Cda S, 1995
)
2.03
"Fencamfamine (FCF) is a psychostimulant drug classified as an indirect dopamine agonist. "( Daily variation in plasma concentration of fencamfamine and striatal dopamine receptors in rats.
Aizenstein, ML; DeLucia, R; Oliveira, GH; Planeta, CS, 1994
)
1.99
"Fencamfamine (FCF) is a CNS stimulant that facilitates central dopaminergic transmission primarily through blockade of dopamine uptake. "( The behavioral sensitization induced by fencamfamine is not related to plasma drug levels.
Aizenstein, ML; DeLucia, R; Planeta, CS, 1995
)
2
"Fencamfamine (FCF) is a central stimulant that facilitates central dopaminergic transmission through inhibition of dopamine uptake and enhanced release of the transmitter. "( Circadian time-dependent effects of fencamfamine on inhibition of dopamine uptake and release in rat striatal slices.
Aizenstein, ML; DeLucia, R; Ferreira, MP; Planeta, CS; Scavone, C, 1997
)
2.01
"Fencamfamine (FCF) is a psychostimulant classified as an indirect dopaminergic agonist. "( Behavioral and neurochemical effects of fencamfamine on rats: a chronobiologic approach.
Aizenstein, ML; DeLucia, R; Planeta, Cda S; Scavone, C, 1989
)
1.99
"Fencamfamine appears to be an indirect DA agonist which interacts with both vesicular and newly synthesized DA storage pools."( Effects of fencamfamine on single unit activity of mesencephalic dopaminergic neurons in rats.
Matthews, RT, 1988
)
1.39

Actions

ExcerptReferenceRelevance
"Fencamfamine may also cause a rapid desensitization to the effects of DA autoreceptor stimulation."( Effects of fencamfamine on single unit activity of mesencephalic dopaminergic neurons in rats.
Matthews, RT, 1988
)
1.39

Treatment

Fencamfamine treatment increased stereotyped sniffing and decreased rearing behaviour. Apomorphine potentiated the effect of apomorphine (0.02 mg/kg, sc) in reducing striatal levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC)

ExcerptReferenceRelevance
"Fencamfamine treatment decreased (34.8 +/- 3.2 vs 25.8 +/- 2.8, P less than 0.05) the stereotyped behavior induced by apomorphine (2.0 mg/kg, sc), but potentiated the effect of apomorphine (0.02 mg/kg, sc) in reducing the striatal levels of homovanillic acid (HVA) (0.41 +/- 0.02 micrograms/g vs 0.31 +/- 0.03 micrograms/g, P less than 0.01) and dihydroxyphenylacetic acid (DOPAC) (0.45 +/- 0.04 micrograms/g vs 0.34 +/- 0.03 micrograms/g, P less than 0.01)."( On the mechanism which mediates the effects of long-term administration of fencamfamine in rats.
Aizenstein, ML; DeLucia, R; Planeta, CS; Scavone, C, 1989
)
1.23
"Fencamfamine treatment increased stereotyped sniffing and decreased rearing behaviour."( Behavioural effects of long-term administration of fencamfamine: neurochemical implications.
Aizenstein, ML; De Lucia, R; Planeta, CS; Scavone, C, 1987
)
1.25

Dosage Studied

ExcerptRelevanceReference
") yielded an inverse dose-response relationship regarding LI."( Effects of fencamfamine on latent inhibition.
Alves, CR; Delucia, R; Silva, MT, 2002
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID118199In vivo nicotinic antagonism relative to (+/-)-exo-mecamylamine measured in mice; stimulant1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system.
AID23495Partition coefficient (logP)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (56.36)18.7374
1990's14 (25.45)18.2507
2000's5 (9.09)29.6817
2010's5 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.45 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index45.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (8.93%)5.53%
Reviews1 (1.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]